AR049977A1 - Uso terapeutico de la toxina botulinica - Google Patents

Uso terapeutico de la toxina botulinica

Info

Publication number
AR049977A1
AR049977A1 ARP050102875A ARP050102875A AR049977A1 AR 049977 A1 AR049977 A1 AR 049977A1 AR P050102875 A ARP050102875 A AR P050102875A AR P050102875 A ARP050102875 A AR P050102875A AR 049977 A1 AR049977 A1 AR 049977A1
Authority
AR
Argentina
Prior art keywords
therapeutic use
stones
botulin toxin
gland
gallstones
Prior art date
Application number
ARP050102875A
Other languages
English (en)
Original Assignee
Ipsen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Ltd filed Critical Ipsen Ltd
Publication of AR049977A1 publication Critical patent/AR049977A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente se relaciona con el uso de una sustancia bloqueante neuromuscular presináptica en la preparacion de un medicamento propuesto para el tratamiento de una glándula, de un organo o de un conducto obstruidos por un cálculo formado naturalmente. Este método se puede aplicar, en particular, en cálculos de las glándulas salivales, cálculos biliares, cálculos renales y cálculos pancreáticos.
ARP050102875A 2004-07-12 2005-07-12 Uso terapeutico de la toxina botulinica AR049977A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0415490A GB2417419A (en) 2004-07-12 2004-07-12 Therapeutic use of Botulinum toxin

Publications (1)

Publication Number Publication Date
AR049977A1 true AR049977A1 (es) 2006-09-20

Family

ID=32865774

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102875A AR049977A1 (es) 2004-07-12 2005-07-12 Uso terapeutico de la toxina botulinica

Country Status (10)

Country Link
US (1) US7838009B2 (es)
EP (1) EP1773378B1 (es)
JP (1) JP4950044B2 (es)
AR (1) AR049977A1 (es)
AT (1) ATE380556T1 (es)
CA (1) CA2573441A1 (es)
DE (1) DE602005003836T2 (es)
ES (1) ES2297730T3 (es)
GB (1) GB2417419A (es)
WO (1) WO2006005912A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556796C (en) 2005-03-03 2018-01-23 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
JP2010519211A (ja) * 2007-02-15 2010-06-03 アラーガン、インコーポレイテッド 膀胱もしくは前立腺障害または多汗症を処置するためのボツリヌス毒素および酵素の使用
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US7455845B2 (en) * 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
ATE282959T1 (de) * 1998-07-06 2004-12-15 Nanobac Oy Verfahren zur beseitigung von nanobakterien
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration

Also Published As

Publication number Publication date
WO2006005912A3 (en) 2006-04-20
DE602005003836D1 (de) 2008-01-24
JP2008505962A (ja) 2008-02-28
WO2006005912A2 (en) 2006-01-19
US7838009B2 (en) 2010-11-23
EP1773378A2 (en) 2007-04-18
EP1773378B1 (en) 2007-12-12
CA2573441A1 (en) 2006-01-19
ES2297730T3 (es) 2008-05-01
GB2417419A (en) 2006-03-01
DE602005003836T2 (de) 2009-01-15
ATE380556T1 (de) 2007-12-15
JP4950044B2 (ja) 2012-06-13
GB0415490D0 (en) 2004-08-11
US20080292661A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
CY2014023I2 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
AR049977A1 (es) Uso terapeutico de la toxina botulinica
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BR0210628A (pt) Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
CY1109972T1 (el) Χρηση τοξινης αλλαντιασης για τη θεραπευτικη αγωγη του πονου της νεραλγιας
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE540690T1 (de) Insulinkombinationen
PE20050477A1 (es) Terapia de combinacion para la infeccion de hcv
ATE430586T1 (de) Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
ITBS20040068A1 (it) Composizione cosmetica e/o farmaceutica per il trattamento della rosacea
DK1545609T3 (da) Antistoffer rettet mod oxideret apolipoprotein B
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
EA200400197A1 (ru) Способы получения поливалентных бактериофагов для лечения бактериальных инфекций
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
DE60130659D1 (de) Therapeutische verbindungen und verfahren
BR0111785A (pt) Composições e métodos para tratamento de candidìase
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
CY1107038T1 (el) Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης
EA200500175A1 (ru) Соль морфин-6-глюкуронида

Legal Events

Date Code Title Description
FB Suspension of granting procedure